Last reviewed · How we verify
Drug resistant tuberculosis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Sirturo | bedaquiline | Janssen Therap | Diarylquinoline Antimycobacterial | Potassium voltage-gated channel subfamily H member 2 | 2012-01-01 | |
| Deltyba | delamanid | Pfizer Inc. | delamanid |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Janssen Therap · 1 drug in Drug resistant tuberculosis
- Pfizer Inc. · 1 drug in Drug resistant tuberculosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Drug resistant tuberculosis:
- Drug resistant tuberculosis treatment updates — RSS
- Drug resistant tuberculosis treatment updates — Atom
- Drug resistant tuberculosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Drug resistant tuberculosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/drug-resistant-tuberculosis. Accessed 2026-06-10.
Related
- Drug resistant tuberculosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing